Considerations and development of topical microbicides to inhibit the sexual transmission of HIV

@article{Turpin2002ConsiderationsAD,
  title={Considerations and development of topical microbicides to inhibit the sexual transmission of HIV},
  author={J. Turpin},
  journal={Expert Opinion on Investigational Drugs},
  year={2002},
  volume={11},
  pages={1077 - 1097}
}
  • J. Turpin
  • Published 2002
  • Medicine
  • Expert Opinion on Investigational Drugs
The increased incidence of HIV/AIDS disease in women aged 15 – 49 years has identified the urgent need for a female-controlled, efficacious and safe vaginal topical microbicide. To meet this challenge, new topical microbicide candidates consisting of molecules or formulations that modify the genital environment (BufferGel™, engineered Lactobacillus, over-the-counter lubricants), surfactants (C31D/Savvy™, sodium dodecyl sulfate, sodium lauryl sulfate), polyanionic polymers (PRO 2000… Expand
BIOPHARMACEUTICAL MICROBICIDES FOR TOPICAL HIV PREVENTION:PRE-CLINICAL EVALUATIONS AND FORMULATION DEVELOPMENT
TLDR
This work investigated two biomolecule (protein/peptide) microbicide candidates: PSC-RANTES, a chemokine analog of RANTES; and RC-101, a circular theta-defensin analog, and hypothesized that the use of a drug delivery system will protect the microbicides candidate against degradation before administration, and in biological fluids after administration, while maintaining drug activity. Expand
Safety Assessment of Microbicide 2P23 on the Rectal and Vaginal Microbiota and Its Antiviral Activity on HIV Infection
  • Zhengqin Gao, Rui Fu, Xiaobo Li, Ji Wang, Yuxian He
  • Medicine
  • Frontiers in Immunology
  • 2021
Containment of the AIDS pandemic requires reducing HIV transmission. HIV infection is initiated by the fusion of the membrane between the virus and the cell membrane of the host. 2P23 is an effectiveExpand
Development of topical microbicides to prevent the sexual transmission of HIV.
Women comprise almost 50% of the population of people living with HIV and the majority of these women contracted the virus through sexual transmission in monogamous relationships in the developingExpand
Guiding the vaginal microbicide trials with biomarkers of inflammation
  • R. Fichorova
  • Biology, Medicine
  • Journal of acquired immune deficiency syndromes
  • 2004
TLDR
Coll cytokine patterns as potential biomarkers of vaginal inflammation are discussed, which are needed for the safety evaluation of topical microbicide products for the prevention of sexually transmitted HIV-1 infection, and it is shown that vaginal formulations, temperature and matrix-specific factors in the vaginal fluids may interfere with cytokine detection. Expand
Candidate Topical Microbicides Bind Herpes Simplex Virus Glycoprotein B and Prevent Viral Entry and Cell-to-Cell Spread
TLDR
The results indicate that PRO 2000, polystyrene sulf onate, cellulose sulfate, and polymethylenehydroquinone sulfonate inhibit HSV infection 10,000-fold and are active against clinical isolates, including an acyclovir-resistant variant. Expand
Vaginal microbicides: A novel approach to preventing sexual transmission of HIV
TLDR
This update to microbicide research and development is described, including preclinical screening algorithms, ideal properties, compounds in the pipeline, and future prospects, based on a previous work. Expand
Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.
TLDR
A gel formulation to deliver a combination microbicide of IQP-0528 and TFV that has significant potential to prevent infection of HIV-1 is identified. Expand
Development of Dual-Acting Pyrimidinediones as Novel and Highly Potent Topical Anti-HIV Microbicides
TLDR
The pyrimidinediones represent excellent microbicide candidates in light of their significantly high efficacies against HIV-1 (subnanomolar concentration range), potencies, solubility profiles, and dual mechanism of antiviral action that includes two early steps of virus replication prior to the integration of the virus that are considered most important for microbicidal activity. Expand
Effects of physiological fluids on physical-chemical characteristics and activity of topical vaginal microbicide products.
TLDR
Results showed that pH was not affected when products were diluted with VFS; however, increases in pH were observed following CMS dilution, and viscosity was significantly decreased for all the dilutions tested excepted for some of the liposome products. Expand
Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides.
TLDR
In vitro, the anti-HIV-1 activity of two leading polyanionic microbicides combined with other antiretroviral agents with microbicidal potential indicate that PRO 2000 and DS can act synergistically with most inhibitors tested, although the degree of synergy depends on inhibitor concentration and combination. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 275 REFERENCES
Recommendations for the clinical development of topical microbicides: an update
TLDR
The clinical section of a general guidance for the development and evaluation of microbicidal products that was first published by the International Working Group on Microbicides (IWGM) in 1996 is updated. Expand
Development of vaginal microbicides for the prevention of heterosexual transmission of HIV.
  • R. Pauwels, E. De Clercq
  • Medicine
  • Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association
  • 1996
TLDR
Combination of two or more of these compounds seems to be an attractive approach to interrupt transmission of HIV at different stages of the infectious process. Expand
Design of a "microbicide" for prevention of sexually transmitted diseases using "inactive" pharmaceutical excipients.
The human immunodeficiency virus (HIV-1) pandemic has been driven primarily by the sexual transmission of the virus, and facilitated by prior infections with other sexually transmitted disease (STD)Expand
DABOs as candidates to prevent mucosal HIV transmission.
TLDR
A long-term assay is described which enables the establishment of whether the above drugs reversibly ( virustatic action) or irreversibly (virucidal action) inhibit HIV-1 multiplication, thus allowing screening for effective and potent microbicides. Expand
The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission.
TLDR
In vitro and in vivo model systems are identified for monitoring undesirable proinflammatory effects of microbicides and other vaginal products to link N-9-induced vaginal inflammation to increased risk of HIV-1 infection. Expand
A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.
TLDR
In this phase I study PRO 2000 gel was found to be generally well tolerated with promising local and systemic safety profiles and Phase II studies are about to begin in sexually active women. Expand
The development of microbicides for clinical use to prevent sexually transmitted diseases
TLDR
The history and current status of the microbicide field is discussed with emphasis on the lessons learned from recent clinical trials, along with anemphasis on the mechanisms involved in the sexual transmission of HIV and how this information influences microbicides development. Expand
Practical prevention of vaginal and rectal transmission of HIV by adapting the oral defense: use of commercial lubricants.
TLDR
To reduce the sexual transmission of HIV by mimicking saliva's targeting of the transmitting infected leukocytes and any cell-free HIV in seminal fluid, the anti-HIV activity of commercially available, over-the-counter lubricants and vaginal preparations that are judged safest by the U.S. Food and Drug Administration are studied. Expand
Novel Thiourea Compounds as Dual-Function Microbicides
TLDR
It is concluded that as potent anti-HIV agents with SIA and reduced cytotoxicity when compared with N-9, the phenyl-substituted and cyclohexenyl-based thiourea derivatives show unique clinical potential to become the active ingredients of a vaginal contraceptive for women who are at high risk for acquiring HIV by heterosexual vaginal transmission. Expand
Phase 1 Trial of the Topical Microbicide BufferGel: Safety Results From Four International Sites
TLDR
BufferGel appears to be safe and well tolerated by the cervicovaginal epithelium, and its effect on BV and yeasts merits further study. Expand
...
1
2
3
4
5
...